X0206 3 2023-07-10 0 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001743122 Prout Samantha C/O AMICUS THERAPEUTICS, INC. 3675 MARKET STREET PHILADELPHIA PA 19104 0 1 0 0 Chief Accounting Officer Common Stock 137003 D Stock Options (right to buy) 14.88 2028-03-26 Common Stock 2940 D Stock Options (right to buy) 10.04 2029-01-02 Common Stock 2376 D Stock Options (right to buy) 9.55 2030-01-02 Common Stock 7566 D Stock Options (right to buy) 10.03 2030-04-15 Common Stock 13768 D Stock Options (right to buy) 21.78 2031-01-04 Common Stock 16963 D Stock Options (right to buy) 12.11 2032-01-14 Common Stock 56711 D Stock Options (right to buy) 11.93 2033-01-03 Common Stock 55203 D The amount shown on this line represents Restricted Stock Units which will vest in varying quantities over the next four years, subject in each case to Ms. Prout's continued service with the Company through the applicable vesting dates. All of the options shown on this line are fully vested and exercisable. These options were granted on January 2, 2020, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 5,670 options are vested and exercisable and 1,896 remain unvested. These options were granted on April 15, 2020, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 10,878 options are vested and exercisable and 2,890 remain unvested. These options were granted on January 4, 2021, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 10,594 options are vested and exercisable and 6,369 remain unvested. These options were granted on January 14, 2022, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 21,263 options are vested and exercisable and 35,448 remain unvested. These options were granted on January 3, 2023, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. All of the options shown on this line are unvested. /s/ Christian Formica, Attorney-in-Fact 2023-07-14